Quantify Research

Quantify Research 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐰𝐢𝐭𝐡 Inka Health 𝐭𝐨 𝐄𝐥𝐞𝐯𝐚𝐭𝐞 𝐑𝐞𝐚𝐥-𝐖𝐨𝐫𝐥𝐝 𝐄𝐯𝐢𝐝𝐞𝐧𝐜𝐞 𝐚𝐧𝐝 𝐇𝐄𝐎𝐑 𝐂𝐚𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬 Quantify Research is pleased to announce a new strategic partnership with Inka Health, a leader in health outcomes research providing advanced analytical solutions that support evidence-based decision-making. This collaboration is designed to combine the strengths of both companies to deliver enhanced analytical solutions and software tools to the healthcare sector. Quantify Research, headquartered in Stockholm, Sweden, is renowned for its ability to conduct comprehensive RWE studies and its innovative approach to evidence synthesis. With a deep understanding of the European healthcare landscape, Quantify Research brings a wealth of experience in executing high-quality, large-scale studies that inform healthcare policy and decision-making. Inka Health, with its advanced analytical capabilities and expertise in HEOR, views this partnership as an opportunity to expand its service offerings. By collaborating with Quantify Research, Inka Health aims to leverage its strengths in analytics to support and enhance Quantify's projects, particularly in the development of synthetic data generation platforms and other internal software tools. “The partnership with Quantify Research is a strategic step forward for Inka Health,” said Paul Arora, CEO of Inka Health. “Together, we are poised to deliver innovative solutions that address the complex needs of healthcare stakeholders, ensuring that our combined efforts lead to more informed and effective healthcare decisions.” Quantify Research is equally enthusiastic about the partnership. “Inka Health’s advanced analytical expertise and experience is a perfect complement to our work in RWE and HEOR,” said Kirk Geale, CEO of Quantify Research. “This collaboration will enable us to offer even more robust and comprehensive solutions to our clients across Europe and beyond.” This partnership underscores Quantify Research’s commitment to driving innovation in healthcare analytics and its dedication to fostering strategic alliances that enhance its ability to deliver cutting-edge solutions. The joint efforts of Inka Health and Quantify Research are expected to make a significant impact on the field, offering advanced tools and insights that meet the evolving needs of the healthcare industry. Quantify Research info@quantifyresearch.com www.quantifyresearch.com

𝐃𝐨𝐧'𝐭 𝐦𝐢𝐬𝐬 𝐨𝐮𝐭! 𝐋𝐢𝐦𝐢𝐭𝐞𝐝 𝐬𝐩𝐨𝐭𝐬 𝐫𝐞𝐦𝐚𝐢𝐧𝐢𝐧𝐠 𝐟𝐨𝐫 𝐨𝐮𝐫 𝐞𝐯𝐞𝐧𝐭 “𝐇𝐨𝐰 𝐜𝐚𝐧 𝐑𝐖𝐄 𝐛𝐞 𝐮𝐬𝐞𝐝 𝐢𝐧 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐭𝐨 𝐭𝐡𝐞 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 𝐂𝐨𝐮𝐧𝐜𝐢𝐥?” Quantify Research is excited to host its next morning meeting on 9 October in #Copenhagen! Denmark has unique registry data, but there is uncertainty about how to best use it to create quality evidence for decision-making. In this session, we will explore the possibilities in this rapidly evolving area at this meeting. We are happy to have a truly fantastic panel of speakers including Niels Christian Hirsch (Quantify Research), Christian Dehlendorff (Medicinrådet), Prof Celeste Porsbjerg (Bispebjerg Hospital), Louise Broe (Lif - Lægemiddelindustriforeningen) and Mary Rosenzweig (Quantify Research). Keep your eyes on this space to meet each of them in a follow-up post. Interest has been high for this in-person meeting, but a there are still a few spots left for some lucky individuals. Don’t miss out on this unique opportunity to learn and network with industry leaders – Use this link to register: https://lnkd.in/dXUfwvid Didn’t manage to secure a spot this time? If you want to be on the guest list for our next event, send us an email and we will keep you up to date. Quantify Research info@quantifyresearch.com www.quantifyresearch.com

Although we didn’t win the obscenely difficult quiz night on Tuesday (there wasn’t even one question about health economics or epidemiology!), the Quantify team did score highest in team spirit 😊

𝐓𝐡𝐚𝐧𝐤𝐬 𝐟𝐨𝐫 𝐚𝐧𝐨𝐭𝐡𝐞𝐫 𝐠𝐫𝐞𝐚𝐭 𝐈𝐒𝐏𝐄 𝐀𝐧𝐧𝐮𝐚𝐥! Jessica Young from Quantify Research's Stockholm office had a fantastic time at last week's International Society for Pharmacoepidemiology's annual meeting, reconnecting with colleagues, meeting new faces, and diving into engaging discussions around the role of pharmacoepidemiology in supporting healthcare decision making. Do any of Jess's sessions catch your eye? Don't hesitate to reach out and learn more. We're already looking ahead to #ISPE 2025 in Washington, DC. What stood out for you at ISPE this year? Share your highlights in the comments below—we'd love to hear your thoughts!

Last week the team came together to give the office plants some much needed TLC. Turns out there are a fair few green fingers at Quantify! 🌿 Whilst we might not be adding gardening to our service offering any time soon, we hope that visitors to the Stockholm office will enjoy our jungle of plants just as much as we do. 🌻 Quantify Research info@quantifyresearch.com www.quantifyresearch.com

We're #hiring a new Finnish speaking Senior Research Analyst in to join our team in Helsinki. Apply today or share this post with your network. Quantify Research info@quantifyresearch.com www.quantifyresearch.com

📢 𝐐𝐮𝐚𝐧𝐭𝐢𝐟𝐲’𝐬 Mathias Lilja 𝐚𝐧𝐝 Johan Mesterton 𝐚𝐫𝐞 𝐜𝐨-𝐚𝐮𝐭𝐡𝐨𝐫𝐬 𝐨𝐧 𝐚 𝐧𝐞𝐰 𝐬𝐭𝐮𝐝𝐲 𝐨𝐧 𝐜𝐲𝐭𝐚𝐫𝐚𝐛𝐢𝐧𝐞 𝐝𝐨𝐬𝐢𝐧𝐠 𝐟𝐨𝐫 𝐭𝐫𝐞𝐚𝐭𝐢𝐧𝐠 𝐬𝐞𝐜𝐨𝐧𝐝𝐚𝐫𝐲 𝐚𝐧𝐝 𝐡𝐢𝐠𝐡-𝐫𝐢𝐬𝐤 𝐀𝐌𝐋 𝐮𝐬𝐢𝐧𝐠 𝐚 𝐬𝐲𝐧𝐭𝐡𝐞𝐭𝐢𝐜 𝐜𝐨𝐧𝐭𝐫𝐨𝐥 𝐚𝐫𝐦 𝐬𝐭𝐮𝐝𝐲 𝐝𝐞𝐬𝐢𝐠𝐧 Since the 1980’s, the standard treatment of acute myeloid leukemia (AML) is cytarabine infusion with anthracycline (7 + 3 regimen). Our latest research at Quantify aimed to assess if higher cytarabine dosing in induction may provide a benefit in older patients with secondary and high-risk AML compared with the standard 7 + 3 regimen. To address this question, we collaborated with national clinical experts to leverage a synthetic control arm approach, combining unique data from the Swedish AML registry, including granular information on patient characteristics, treatments, and outcomes, with clinical trial data from the US and Canada. This study fills an important gap in the evidence base and offers new insights into treatment strategies for this vulnerable patient population. 🆕 What’s New? Quantify's recent study compared two key treatment protocols: ·      Standard 7+3 Regimen: 100 mg/m² cytarabine via continuous infusion for 7 days, plus 60 mg/m² daunorubicin for the first 3 days. ·      Swedish Standard-of-Care:1g/m² cytarabine twice daily for 7 days, along with 60 mg/m² daunorubicin administered in eight-hour infusions for the first 3 days. 🔍 Key Strength: A key challenge in any study of drug effectiveness—particularly when using external comparators—is ensuring that the study groups have similar characteristics. This study ensured comparability by aligning the Swedish AML registry patients with the trial’s eligibility criteria and through propensity scoring, including age, sex, and indicators of disease activity as matching variables. 📊 Key Findings: Our results suggest that intensified cytarabine dosing during induction is feasible also in high-risk older AML patients without increased early mortality and with beneficial long-term survival. 🤝 Connect with us: With extensive experience in conducting rigorous observational studies in pharmacoepidemiology, Quantify is your trusted partner for impactful research. Reach out to discuss how we can support your next project! Head over to our website for a link to the full article! https://lnkd.in/dnb2Q5Ch Quantify Research info@quantifyresearch.com www.quantifyresearch.com

𝐏𝐫𝐨𝐮𝐝 𝐭𝐞𝐚𝐦 𝐦𝐨𝐦𝐞𝐧𝐭 🌟 Last week a whooping 3 teams of Quantify Research colleagues took part in the annual Convini relay race in Stora Skuggan in Stockholm - our biggest turnout yet! A relay race truly embodies what we at Quantify are all about as you can't complete a relay without a strong team that works well together 🙌 Well done to everyone who took part! Kelsi Smith, Nicholas Norton, Jonas Banefelt, Mathias Lilja, Béranger Lueza, Alexandra Cooper, Fredrik Borgström, Linnea Oldsberg, Marcelina Kądziela, Liina Salovaara, Helena Skröder Löveborn, Ana Buzatu, Kirk Geale Quantify Research info@quantifyresearch.com www.quantifyresearch.com

𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐧𝐞𝐰𝐬 𝐟𝐨𝐫 𝐭𝐡𝐨𝐬𝐞 𝐥𝐨𝐨𝐤𝐢𝐧𝐠 𝐭𝐨 𝐞𝐧𝐡𝐚𝐧𝐜𝐞 𝐭𝐡𝐞𝐢𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 𝐀𝐜𝐜𝐞𝐬𝐬 𝐚𝐧𝐝 𝐑𝐞𝐚𝐥 𝐖𝐨𝐫𝐥𝐝 𝐄𝐯𝐢𝐝𝐞𝐧𝐜𝐞 (𝐑𝐖𝐄) 𝐞𝐟𝐟𝐨𝐫𝐭𝐬 𝐢𝐧 𝐅𝐢𝐧𝐥𝐚𝐧𝐝! Our capabilities have significantly expanded, allowing us to offer comprehensive support for your Finnish data and access needs. As the leading provider of Nordic RWE and market access services, we’ve strengthened our Finnish presence to deliver: ▪ End-to-end RWE including patient-level data access, biobanks, Findata permits, statistical analyses, reporting, manuscripts, and other medical communications ▪ Economic modelling, reimbursement dossiers, and strategic support to ensure your product reaches patients in need, through PPB or hospital channels ▪ Expert medical writing, systematic literature reviews, and meta-analyses to make sense of the high volume of research and HTA decisions, to support internal decision making, medical teams, and create strong value messaging Quantify’s experts can help you align your Finnish strategy with a broader market access approach and put Finnish RWD in the context of other potential data sources globally. Ready to succeed in Finland and beyond? Get in touch with our local Finnish experts Ville Perälä and Katja Nolvi to discuss your current needs and priorities.   𝐉ä𝐧𝐧𝐢𝐭𝐭ä𝐯𝐢ä 𝐮𝐮𝐭𝐢𝐬𝐢𝐚 𝐧𝐢𝐢𝐥𝐥𝐞, 𝐣𝐨𝐭𝐤𝐚 𝐡𝐚𝐥𝐮𝐚𝐯𝐚𝐭 𝐭𝐞𝐡𝐨𝐬𝐭𝐚𝐚 𝐥ää𝐤𝐤𝐞𝐢𝐝𝐞𝐧 𝐦𝐚𝐫𝐤𝐤𝐢𝐧𝐨𝐢𝐥𝐥𝐞𝐩ää𝐬𝐲ä 𝐣𝐚 𝐑𝐞𝐚𝐥 𝐖𝐨𝐫𝐥𝐝 𝐄𝐯𝐢𝐝𝐞𝐧𝐜𝐞 (𝐑𝐖𝐄) -𝐭𝐮𝐭𝐤𝐢𝐦𝐮𝐬𝐭𝐚𝐚𝐧 𝐒𝐮𝐨𝐦𝐞𝐬𝐬𝐚! Resurssimme ovat laajentuneet Suomessa merkittävästi, joten voimme tarjota kattavan tuen RWE- ja Market Access-tarpeisiisi. Pohjoismaiden johtavana RWE- ja Market Access-palveluiden tarjoajana olemme vahvistaneet organisaatiotamme Suomessa tuottaaksemme: ▪ End-to-end RWE-projektit, mukaan lukien potilastason tietojen käyttö, biopankit, Findata-luvat, tilastolliset analyysit, raportointi, julkaisut ja muu lääketieteellinen viestintä ▪ Taloudellinen mallinnus, korvattavuushakemukset ja strateginen tuki sen varmistamiseksi, että tuotteesi tavoittaa sitä tarvitsevat potilaat, joko Hila- tai sairaalakanavan kautta ▪ Asiantuntevat lääketieteellisen kirjoittamisen palvelut, systemaattiset kirjallisuuskatsaukset ja meta-analyysit laajan tutkimustiedon ja HTA-päätösten ymmärtämiseksi. Näitä voitte käyttää sisäiseen päätöksentekoon, lääketieteellisten osastojen tukemiseksi ja vahvan arvoviestinnän luomiseksi Quantifyn asiantuntijat voivat auttaa sinua asettamaan suomalaisen Access-suunnitelmasi linjaan globaalin suunnitelmasi kanssa ja asettamaan suomalaisen RWD:n muiden mahdollisten tietolähteiden rinnalle maailmanlaajuisesti. Oletko valmis menestymään Suomessa ja sen ulkopuolella? Ota yhteyttä paikallisiin suomalaisiin asiantuntijoihimme Ville Perälä tai Katja Nolvi keskustellaksesi tämänhetkisistä tarpeistasi.

𝐐𝐮𝐚𝐧𝐭𝐢𝐟𝐲 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬 𝐰𝐢𝐭𝐡 𝐆𝐲𝐥𝐟𝐢 Ó𝐥𝐚𝐟𝐬𝐬𝐨𝐧 𝐭𝐨 𝐩𝐫𝐨𝐯𝐢𝐝𝐞 𝐈𝐜𝐞𝐥𝐚𝐧𝐝𝐢𝐜 𝐇𝐄𝐎𝐑 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 Quantify Research is excited to announce a new partnership with Gylfi Ólafsson, an expert in the Icelandic health care system and RWD landscape.  Gylfi holds a PhD from Karolinska Institutet and has previously worked as health economist at Quantify Research and as the CEO of the Westfjords Healthcare Institution in Iceland. This collaboration extends Quantify’s truly unparalleled ability to offer Nordic HEOR services. In addition to our expertise, offices and local staff in Denmark, Norway, Finland and Sweden, we are now proud to offer our clients complementary insights and strategic advice for Iceland. Iceland also has a unique RWD offering of interest to both local and global pharma. Do you need Nordic-wide RWE, reimbursement, or strategic support? Get in touch with us to find out more! Quantify Research info@quantifyresearch.com www.quantifyresearch.com